Setmelanotide Acetate

N/A

Report date: 2026/04/17 20:02:02
NMEFirst In Class

Base Information

Drug NameSetmelanotide Acetate
Drug Alias Name塞美兰肽setmelanotida司美诺肽setmelanotidumSetmelanotide +[10] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionMelanocortin receptor 4 agonists
TargetsMelanocortin receptor 4
Therapy Area/IndicationsHypothalamic ObesityCombined pituitary hormone deficiencyHyperphagia +[14] 
Global Approved IndicationsObesityBardet-Biedl Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/11/25
Country/TerritoryCanadaUnited StatesPuerto Rico +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesIpsen
China Registration ClassN/A

Develop Information

Active CompaniesMedison PharmaRhythm Pharmaceuticals Netherlands BVRareStone Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsHypothalamic ObesityCombined pituitary hormone deficiencyHyperphagia +[9] 
Inactive IndicationsOverweightObesity, MorbidHypertriglyceridemia +[5] 

Other Information

ATC CodeA08AX
Related LinksWikipediaDrugBankKEGG